Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Tonix Pharm Holdings (TNXP)

Tonix Pharm Holdings (TNXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032 FinancialNewsMedia - Thu Feb 15, 7:45AM CST

EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NYSE:MRK) EQNX::TICKER_END

TNXP : 0.1600 (+1.91%)
PFE : 26.00 (+2.40%)
LLY : 726.31 (-2.63%)
ABBV : 166.41 (+1.06%)
MRK : 125.78 (+0.44%)
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032 GlobeNewswire - Thu Feb 15, 7:45AM CST

TNXP : 0.1600 (+1.91%)
PFE : 26.00 (+2.40%)
LLY : 726.31 (-2.63%)
ABBV : 166.41 (+1.06%)
MRK : 125.78 (+0.44%)
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease PressReach - Wed Oct 5, 2022

A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease, announcing recently that it has gotten approval from Argentina’s regulators to begin a Phase ll clinical...

OPTI.CN : 0.2650 (+1.92%)
SEEL : 0.3345 (-1.04%)
NUMI.TO : 0.0850 (-5.56%)
NUMIF : 0.0605 (-5.76%)
ATAI : 1.8500 (-3.14%)
OPTHF : 0.1934 (+3.98%)
TNXP : 0.1600 (+1.91%)
TAK : 13.24 (+0.61%)
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease FinancialNewsMedia - Wed Oct 5, 2022

FN Media Group Presents Microsmallcap.com Market Commentary   New York, NY – October 5, 2022 – A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease,...

SEEL : 0.3345 (-1.04%)
TAK : 13.24 (+0.61%)
ATAI : 1.8500 (-3.14%)
TNXP : 0.1600 (+1.91%)
OPTI.CN : 0.2650 (+1.92%)
OPTHF : 0.1934 (+3.98%)
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer's Disease PR Newswire - Wed Oct 5, 2022

/PRNewswire/ -- A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer's disease, announcing recently that it has gotten...

OPTI.CN : 0.2650 (+1.92%)
OPTHF : 0.1934 (+3.98%)
SEEL : 0.3345 (-1.04%)
TAK : 13.24 (+0.61%)
ATAI : 1.8500 (-3.14%)
TNXP : 0.1600 (+1.91%)
Psychedelics Use Among Young Adults Reaches All-Time High FinancialNewsMedia - Thu Sep 1, 2022

FN Media Group Presents Microsmallcap.com Market Commentary   New York, NY – September 1, 2022 – Young adults are using more hallucinogens than ever.  According to a National Institute of Health...

OPTI.CN : 0.2650 (+1.92%)
OPTHF : 0.1934 (+3.98%)
SEEL : 0.3345 (-1.04%)
NUMI.TO : 0.0850 (-5.56%)
NUMIF : 0.0605 (-5.76%)
ATAI : 1.8500 (-3.14%)
TNXP : 0.1600 (+1.91%)
Psychedelics Use Among Young Adults Reaches All-Time High PR Newswire - Thu Sep 1, 2022

/PRNewswire/ -- Young adults are using more hallucinogens than ever. According to a National Institute of Health survey, the amount of people between age 19 to...

OPTI.CN : 0.2650 (+1.92%)
NUMI.TO : 0.0850 (-5.56%)
OPTHF : 0.1934 (+3.98%)
SEEL : 0.3345 (-1.04%)
NUMIF : 0.0605 (-5.76%)
ATAI : 1.8500 (-3.14%)
TNXP : 0.1600 (+1.91%)
Tonix Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights Globe Newswire - Mon Aug 8, 2022

Phase 1 Study of TNX-801, a Vaccine in Development for the Prevention of Monkeypox and Smallpox, Expected to Initiate in First Half 2023 in Kenya; the U.S....

TNXP : 0.1600 (+1.91%)
Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering Potentiated Intranasal Oxytocin (TNX-1900) for the Treatment of Pain Globe Newswire - Mon Aug 1, 2022

New patent expected to expire in 2036 Phase 2 Study for Prevention of Migraine Headache Expected to Start Second Half 2022 CHATHAM, N.J., Aug. 01, 2022 ...

TNXP : 0.1600 (+1.91%)
Tonix Pharmaceuticals Announces Collaboration with Kenya Medical Research Institute to Develop TNX-801 in Kenya as a Vaccine for the Prevention of Monkeypox and Smallpox Infection Globe Newswire - Thu Jul 28, 2022

Phase 1 Clinical Study Expected to be Initiated in Kenya in the First Half of 2023 World Health Organization Has Declared Monkeypox a Global Health...

TNXP : 0.1600 (+1.91%)

Barchart Exclusives

Up 67% YTD, Is Soundhound AI Overvalued? Barchart - 1 hour ago
Soundhound AI's shares have surged, thanks to Nvidia's investment in the company and growing enthusiasm surrounding AI. After a steep pullback, is the stock still overvalued? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot